PINK - Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels Forecasts Positive For 2024 | Benzinga
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.
Deal volume fell 9% from 242 deals in Q2 2023 to 221 M&A deals in Q3 2023.
PricewaterhouseCoopers wrote in its Pharmaceutical and Life Sciences: U.S. Deals 2024 Outlook. "As regulators' perspectives on key deal factors become better understood, there may be a return of larger deals, along with continued interest in the $5 billion to $15 billion deals to fill targeted strategic gaps."
"Despite some stabilization in the macroeconomic environment and the potential for a soft landing in sight, continued geopolitical and regulatory uncertainty seems a given in 2024," PWC added in its report.
The pharmaceutical and life sciences sector experienced a notably robust year in 2023, nearing pre-pandemic levels in both M&A deal value and volume, the PWC report added.
Anticipations for 2024 suggest continuing this trend, projecting comparable activity levels within the range of $225 ...